Red blood cells (RBCs) and RBC membrane-derived nanoparticles have been historically
developed as bioinspired drug delivery systems to combat the issues of premature …

Cell membranes have recently emerged as a new source of materials for molecular delivery
systems. Cell membranes have been extruded or sonicated to make nanoscale vesicles …

Rational design of nanomedicine to accelerate thrombolysis and sequentially avoid
thrombolysis-mediated reperfusion injury is still a challenge. Here, we develop a biomimetic …

Glioma is the most common malignant primary brain tumor, and the accurate diagnosis of
glioma has always been a challenge. Moreover, cerebellar glioma, which is difficult to be …

Various health agencies, such as the European Medical Agency (EMA), Centers for Disease
Control and Prevention (CDC), and World Health Organization (WHO), timely cited the …

Ischemic stroke is a vascular central nervous system (CNS) disease that leads a disability
and death. Thrombolysis and neuroprotection are the primary treatment strategies of …

Over past decades, nanotechnology has contributed to the biomedical field in areas
including detection, diagnosis, and drug delivery via opto-electronic properties or …

Extensive reports of pulmonary embolisms, ischaemic stroke and myocardial infarctions
caused by coronavirus disease 2019 (COVID-19), as well as a significantly increased long …

Although nanocarriers offer many advantages as drug delivery systems, their poor stability in
circulation, premature drug release and nonspecific uptake in non-target organs have …

Antithrombosis therapy is confronted with short half-lives of thrombolytic agents, limited
therapeutic effects, and bleeding complications. Drug delivery systems of thrombolytic …